Synthesis,in vitroenzyme activity and molecular docking studies of new benzylamine-sulfonamide derivatives as selective MAO-B inhibitors

Creative Commons License

SAĞLIK B. N., OSMANİYE D., Acar cevik U., LEVENT S., Kaya cavusoglu B., Atli Eklioglu O., ...Daha Fazla

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, cilt.35, sa.1, ss.1422-1432, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/14756366.2020.1784892
  • Dergi Adı: JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Food Science & Technology Abstracts, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1422-1432
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Many studies have been conducted on the selective inhibition of human monoamine oxidase B (hMAO-B) enzyme using benzylamine-sulphonamide derivatives. Using various chemical modifications onBB-4h, which was reported previously by our team and showed a significant level of MAO-B inhibition, novel benzylamine-sulphonamide derivatives were designed, synthesised, and their MAO inhibition potentials were evaluated. Among the tested derivatives, compounds4iand4tachieved IC(50)values of 0.041 +/- 0.001 mu M and 0.065 +/- 0.002 mu M, respectively. The mechanism ofhMAO-B inhibition by compounds4iand4twas studied using Lineweaver-Burk plot. The nature of inhibition was also determined to be non-competitive. Cytotoxicity tests were conducted and compounds4iand4twere found to be non-toxic. Molecular docking studies were also carried out for compound4i, which was found as the most potent agent, withinhMAO-B catalytic site.